nefrНефрологияNephrology (Saint-Petersburg)1561-62742541-9439Pavlov First Saint-Petersburg State Medical University10.24884/1561-6274-2014-18-1-20-24nefr-4Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESИндоксил сульфат при хронической болезни почекIndoxyl sulphate at chronic kidney diseaseЛукичёвБ. Г.LukichevB. G.noemail@neicon.ruПодгаецкаяО. Ю.noemail@neicon.ruКаруннаяА. В.KarunnayaA. V.a.v.karunnaya@yandex.ruРумянцевА. Ш.RumyantsevA. Sh.noemail@neicon.ruПервый Санкт-Петербургский государственный медицинский университет им акад. И.П. ПавловаRussian FederationООО Центр семейной медицины «Моника»Russian Federation2014010120141812532Copyright © Лукичёв Б.Г., Подгаецкая О.Ю., Карунная А.В., Румянцев А.Ш., 20142014Лукичёв Б.Г., Подгаецкая О.Ю., Карунная А.В., Румянцев А.Ш.Lukichev B.G., Подгаецкая О.Ю., Karunnaya A.V., Rumyantsev A.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephrolog.ru/jour/article/view/4

В обзоре приведены литературные данные о механизмах токсического действия индоксил сульфата при дисфункции почек.

Literary data about the mechanisms of toxic effect of indoxyl sulfate at kidney disfunction are provided in the review.

индоксил сульфатоксидативный стрессинтерстициальный фиброзсердечно-сосудистые заболеванияостеопорозindoxyl sulfateoxidative stressinterstitial fibrosiscardiovascular diseasesosteoporosisReferencesVanholder R., De Smet R., Glorieux G., et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003; 63 (5): 1934-1943Vanholder R., De Smet R., Glorieux G., et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003; 63 (5): 1934-1943Bergstrom J., Furst P. Uremic toxins. Kidney Int 1978; 8 (Suppl. 1): 9-12Bergstrom J., Furst P. Uremic toxins. Kidney Int 1978; 8 (Suppl. 1): 9-12Rutkowski P. Kliniczne i metaboliczne nastêpstwa zatrucia mocznicowego. Przegl Lek 2006; 63 (4): 209-217Rutkowski P. Kliniczne i metaboliczne nastêpstwa zatrucia mocznicowego. Przegl Lek 2006; 63 (4): 209-217Vanholder R., De Smet R., Lameire NH. Redesigning the map of uremic toxins. Contrib Nephrol 2001; 133: 42-70Vanholder R., De Smet R., Lameire NH. Redesigning the map of uremic toxins. Contrib Nephrol 2001; 133: 42-70Chiang C.K., Tanaka T., Nangaku M. Dysregulated oxygen metabolism of the kidney by uremic toxins: review. J Ren Nutr 2012; 22(1): 77-80Chiang C.K., Tanaka T., Nangaku M. Dysregulated oxygen metabolism of the kidney by uremic toxins: review. J Ren Nutr 2012; 22(1): 77-80Синюхин В.Н., Стецюк Е.А., Арзуманов С.В. Экспериментальная и клиническая урология 2013; 1: 30-35Синюхин В.Н., Стецюк Е.А., Арзуманов С.В. Экспериментальная и клиническая урология 2013; 1: 30-35Cohen G., Glorieux G., Thornalley P. et al. Review on uraemic toxins III. Recommendation for handling uraemic retention solutes in vitro-towards a standardized approach for research on uraemia. NDT 2007; 22: 3381-3390Cohen G., Glorieux G., Thornalley P. et al. Review on uraemic toxins III. Recommendation for handling uraemic retention solutes in vitro-towards a standardized approach for research on uraemia. NDT 2007; 22: 3381-3390Сивков А.В., Синюхин В.Н., Бебешко Е.В. Уремический токсин паракрезол у больных с терминальной стадией ХПН. Экспериментальная и клиническая урология 2012; № 1: 68-71Сивков А.В., Синюхин В.Н., Бебешко Е.В. Уремический токсин паракрезол у больных с терминальной стадией ХПН. Экспериментальная и клиническая урология 2012; № 1: 68-71Vanholder R., Schepers E., Pletinck A. et al. An update on protein-bound uremic retention solutes. J Ren Nutr 2012; 22 (1): 90-94Vanholder R., Schepers E., Pletinck A. et al. An update on protein-bound uremic retention solutes. J Ren Nutr 2012; 22 (1): 90-94Wengle B., Hellström K. Volatile phenols in serum of uraemic patients. Clin Sci 1972; 43: 493-498Wengle B., Hellström K. Volatile phenols in serum of uraemic patients. Clin Sci 1972; 43: 493-498Niwa T. Phenol and p-cresol accomuiated in uremic serum measured by HPLC with fluorescence detection. Clin Chem 1993; 39: 108-111Niwa T. Phenol and p-cresol accomuiated in uremic serum measured by HPLC with fluorescence detection. Clin Chem 1993; 39: 108-111Niwa T., Ise M., Miyazaki T. Progression of glomerular sclerosis in experimental uremic rats by administration of indole, a precursor of indoxyl sulfate. Am J Nephrol 1994; 14(3): 207-212Niwa T., Ise M., Miyazaki T. Progression of glomerular sclerosis in experimental uremic rats by administration of indole, a precursor of indoxyl sulfate. Am J Nephrol 1994; 14(3): 207-212Niwa T., Ise M. Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis. J Lab Clin Med 1994; 124: 96-104Niwa T., Ise M. Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis. J Lab Clin Med 1994; 124: 96-104Hanly P.J., Pierratos A. Improvement of sleep apnea in patients with chronic renal failure who undergo nocturnal hemodialysis. N Engl J Med 2001; 344: 102-107Hanly P.J., Pierratos A. Improvement of sleep apnea in patients with chronic renal failure who undergo nocturnal hemodialysis. N Engl J Med 2001; 344: 102-107Kochanek K.D., Xu J., Murphy S.L., Minino A.M., Kung H.S. Deaths: preliminary Data for 2009. Nat Vital Stat Rep 2011; 4: 59Kochanek K.D., Xu J., Murphy S.L., Minino A.M., Kung H.S. Deaths: preliminary Data for 2009. Nat Vital Stat Rep 2011; 4: 59Foley R.N., Murray A.M., Li S., Herzog C.A., McBean A.M., Eggers P.W., Collins A.J. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005; 16: 489-495Foley R.N., Murray A.M., Li S., Herzog C.A., McBean A.M., Eggers P.W., Collins A.J. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005; 16: 489-495Смирнов А.В., Добронравов В.А., Каюков И.Г. Кардиоренальный континуум: патогенетические основы превентивной нефрологии. Нефрология. 2005; 9(3): 7-15Смирнов А.В., Добронравов В.А., Каюков И.Г. Кардиоренальный континуум: патогенетические основы превентивной нефрологии. Нефрология. 2005; 9(3): 7-15Шутов А.М., Серов В.А. Кардиоренальный и ренокардиальный синдромы. Нефрология 2009; 13(4): 59-63Шутов А.М., Серов В.А. Кардиоренальный и ренокардиальный синдромы. Нефрология 2009; 13(4): 59-63Bammens B., Evenepoel P., Verbeke K. et al. Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relative with uremic symptoms. Kidney Int 2003; 64: 2238-2243Bammens B., Evenepoel P., Verbeke K. et al. Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relative with uremic symptoms. Kidney Int 2003; 64: 2238-2243Bammens B., Evenepoel P., Keuleers H. et al. Free serum concentration of the protein-bound retention solute p-cresol predicts mortality in hemodialysis patients. Kidney Int 2006; 69: 1081-1087Bammens B., Evenepoel P., Keuleers H. et al. Free serum concentration of the protein-bound retention solute p-cresol predicts mortality in hemodialysis patients. Kidney Int 2006; 69: 1081-1087De Smet R., Kaer J. van, Vlem B. et al. Toxicity of free p-cresol: a prospective and cross-sectional analysis. Clin Chemistry 2003; 49: 470-478De Smet R., Kaer J. van, Vlem B. et al. Toxicity of free p-cresol: a prospective and cross-sectional analysis. Clin Chemistry 2003; 49: 470-478Liabeuf S., Drüeke T.B., Massy Z.A. Protein-Bound Uremic Toxins: New Insight from Clinical Studies. Toxins 2011; 3: 911-919Liabeuf S., Drüeke T.B., Massy Z.A. Protein-Bound Uremic Toxins: New Insight from Clinical Studies. Toxins 2011; 3: 911-919Sirich T.L., Luo F.J., Plummer N.S., Hostetter T.H., Meyer T.W. Selectively increasing the clearance of protein-bound uremic solutes. Nephrol Dial Transplant 2012; 27(4): 1574-1579Sirich T.L., Luo F.J., Plummer N.S., Hostetter T.H., Meyer T.W. Selectively increasing the clearance of protein-bound uremic solutes. Nephrol Dial Transplant 2012; 27(4): 1574-1579Bammens B., Evenepoel P., Keuleers H., Verbeke K., Vanrenterghem Y. Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients. Kidney Int 2006; 69: 1081-1087Bammens B., Evenepoel P., Keuleers H., Verbeke K., Vanrenterghem Y. Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients. Kidney Int 2006; 69: 1081-1087Enomoto A., Takeda M., Tojo A. et al. Role of organic anion transporters in the tubular transport of indoxyl sulfate and the induction of its nephrotoxicity. J Am Soc Nephrol 2002; 13: 1711-1720Enomoto A., Takeda M., Tojo A. et al. Role of organic anion transporters in the tubular transport of indoxyl sulfate and the induction of its nephrotoxicity. J Am Soc Nephrol 2002; 13: 1711-1720Cheng-Jui Lin, Chih-Kuang Chuang, Hsuan-Liang Liu et al. The serum levels of P-cresol and Indoxyl sulfate in different hemodialysis vintage. J Clin Medicine and Research 2011; 3(8): 114-119Cheng-Jui Lin, Chih-Kuang Chuang, Hsuan-Liang Liu et al. The serum levels of P-cresol and Indoxyl sulfate in different hemodialysis vintage. J Clin Medicine and Research 2011; 3(8): 114-119Meert N., Beerenhout C., Schepers E., Glorieux G., Kooman J.,Vanholder R. Evolution of protein-bound uraemic solutes during predilution haemofiltration. J Nephrol 2009; 22 (3): 352-357Meert N., Beerenhout C., Schepers E., Glorieux G., Kooman J.,Vanholder R. Evolution of protein-bound uraemic solutes during predilution haemofiltration. J Nephrol 2009; 22 (3): 352-357Fagugli R.M., De Smet R., Buoncristiani U., Lameire N., Vanholder R. Behavior of nonprotein-bound and proteinbound uremic solutes during daily hemodialysis. Am J Kidney Dis 2002; 40 (2): 339-347Fagugli R.M., De Smet R., Buoncristiani U., Lameire N., Vanholder R. Behavior of nonprotein-bound and proteinbound uremic solutes during daily hemodialysis. Am J Kidney Dis 2002; 40 (2): 339-347Martinez A., Recht N., Hostetter T., Meyer T. Removal of p-cresol sulfate by hemodialysis. J Am Soc Nephrol 2005; 16: 3430-3437Martinez A., Recht N., Hostetter T., Meyer T. Removal of p-cresol sulfate by hemodialysis. J Am Soc Nephrol 2005; 16: 3430-3437De Smet R., David F., Sandra P., Van Kaer J. et al. A sensitive HPLC method for the quantification of free and total p-cresol in patients with chronic renal failure. Clin him Acta 1998; 278: 1-21De Smet R., David F., Sandra P., Van Kaer J. et al. A sensitive HPLC method for the quantification of free and total p-cresol in patients with chronic renal failure. Clin him Acta 1998; 278: 1-21De Loor H., Bammens B., Evenepoel P. et al. Gas chromatographic-mass spectrometric analysis for measurement of p-cresol and its conjugated metabolites in uremic and normal serum. Clin Chem 2005; 51(8): 1535-1538De Loor H., Bammens B., Evenepoel P. et al. Gas chromatographic-mass spectrometric analysis for measurement of p-cresol and its conjugated metabolites in uremic and normal serum. Clin Chem 2005; 51(8): 1535-1538Niwa T. Update of uremic toxin research by mass spectrometry. Mass Spectrom 2011; 30(3): 510-521Niwa T. Update of uremic toxin research by mass spectrometry. Mass Spectrom 2011; 30(3): 510-521Niwa T., Miyazaki T., Tsukushi S. et al. Accumulation of indoxil-beta-D-glucuronide in uremic serum: supression of its production by oral sorbent and efficient removal by hemodialysis. Nephron 1996; 74: 72-78Niwa T., Miyazaki T., Tsukushi S. et al. Accumulation of indoxil-beta-D-glucuronide in uremic serum: supression of its production by oral sorbent and efficient removal by hemodialysis. Nephron 1996; 74: 72-78Lin C.J., Wu C.J., Pan C.F. et al. Serum protein-bound uraemic toxins and clinical outcomes in haemodialysis patients. Nephrol Dial Transplant 2010; 25: 3693-3700Lin C.J., Wu C.J., Pan C.F. et al. Serum protein-bound uraemic toxins and clinical outcomes in haemodialysis patients. Nephrol Dial Transplant 2010; 25: 3693-3700Meijers B.K., Bammens B., de Moor et al. Free p-cresol is associated with cardiovascular disease in hemodialysis patients. Kidney Int 2008; 73: 1174-1180Meijers B.K., Bammens B., de Moor et al. Free p-cresol is associated with cardiovascular disease in hemodialysis patients. Kidney Int 2008; 73: 1174-1180Niwa T., Nomura T., Sugiyama S., Miyazaki T., Tsukushi S., Tsutsui S. The protein metabolite hypothesis, a model for the progression of renal failure: an oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients. Kidney Int 1997; 62 (Suppl 1) S23-S28Niwa T., Nomura T., Sugiyama S., Miyazaki T., Tsukushi S., Tsutsui S. The protein metabolite hypothesis, a model for the progression of renal failure: an oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients. Kidney Int 1997; 62 (Suppl 1) S23-S28Sanaka T., Sugino N., Teraoka S., Ota K. Therapeutic effects of oral sorbent in undialyzed uremia. Am J Kidney Dis 1988; 12: 97-103Sanaka T., Sugino N., Teraoka S., Ota K. Therapeutic effects of oral sorbent in undialyzed uremia. Am J Kidney Dis 1988; 12: 97-103Fujii H., Nishijima F., Goto S. et al. Oral charcoal adsorbent (AST-120) prevents progression of cardiac damage in chronic kidney disease through suppression of oxidative stress. Nephrol Dial Transplant 2009; 24: 2089-2095Fujii H., Nishijima F., Goto S. et al. Oral charcoal adsorbent (AST-120) prevents progression of cardiac damage in chronic kidney disease through suppression of oxidative stress. Nephrol Dial Transplant 2009; 24: 2089-2095Lin C.J., Chen H.H., Pan C.F. et al. p-Cresylsulfate and indoxyl sulfate level at different stages of chronic kidney disease. J Clin Lab Anal 2011; 25(3): 191-197Lin C.J., Chen H.H., Pan C.F. et al. p-Cresylsulfate and indoxyl sulfate level at different stages of chronic kidney disease. J Clin Lab Anal 2011; 25(3): 191-197Curtius H.C., Mettler M., Ettlinger L. Study of the intestinal tyrosine metabolism using stable isotopes and gas chromatography-mass spectrometry. J Chromatogr 1976; 126: 569-580Curtius H.C., Mettler M., Ettlinger L. Study of the intestinal tyrosine metabolism using stable isotopes and gas chromatography-mass spectrometry. J Chromatogr 1976; 126: 569-580Vanholder R., Meert N., Schepers E. et al. Review on uraemic solutes II-Variability in reported concentrations: causes and consequences. NDT 2007; 22: 3115-3121Vanholder R., Meert N., Schepers E. et al. Review on uraemic solutes II-Variability in reported concentrations: causes and consequences. NDT 2007; 22: 3115-3121Burchell B., Coughtrie M.W. Genetic and environmental factors associated with variation of human xenobiotic glucuroni-dation and sulfation. Environ Health Perspect 1997; 105 (Suppl. 4): 739-747Burchell B., Coughtrie M.W. Genetic and environmental factors associated with variation of human xenobiotic glucuroni-dation and sulfation. Environ Health Perspect 1997; 105 (Suppl. 4): 739-747Vanholder R., Bammens B., de Loor H. et al. The unfortunate end of p-cresol as a uraemic toxin. Nephrol Dial Transplant 2011; 26(5): 1464-1467Vanholder R., Bammens B., de Loor H. et al. The unfortunate end of p-cresol as a uraemic toxin. Nephrol Dial Transplant 2011; 26(5): 1464-1467Vanholder R., van Laecke S., Glorieux G. What is new in uremic toxicity? Pediatr Nephrol 2008; 23(8): 1211-1221Vanholder R., van Laecke S., Glorieux G. What is new in uremic toxicity? Pediatr Nephrol 2008; 23(8): 1211-1221Meijers B.K., Evenepoel P. The gut-kidney axis: indoxyl sulfate, p-cresyl sulfate and CKD progression. Nephrol Dial Transplant 2011; 26(3): 759-761Meijers B.K., Evenepoel P. The gut-kidney axis: indoxyl sulfate, p-cresyl sulfate and CKD progression. Nephrol Dial Transplant 2011; 26(3): 759-761de Carvalho J.T. Jr, Dalboni M.A., Watanabe R. et al. Effects of spermidine and p-cresol on polymorphonuclear cell apoptosis and function. Artif Organs 2011; 35(2): 27-32de Carvalho J.T. Jr, Dalboni M.A., Watanabe R. et al. Effects of spermidine and p-cresol on polymorphonuclear cell apoptosis and function. Artif Organs 2011; 35(2): 27-32Галишон П., Гертиг А. Эпителиально-мезенхимальная трансформация как биомаркер почечного фиброза: готовы ли мы применить теоретические знания на практике? Нефрология 2013; 17 (4): 9-16Галишон П., Гертиг А. Эпителиально-мезенхимальная трансформация как биомаркер почечного фиброза: готовы ли мы применить теоретические знания на практике? Нефрология 2013; 17 (4): 9-16Miyazaki T., Ise M., Hirata M. et al. Indoxyl sulfate stimulates renal synthesis of transforming growth factor-beta 1 and progression of renal failure. Kidney Int Suppl 1997; 63: S211-S214Miyazaki T., Ise M., Hirata M. et al. Indoxyl sulfate stimulates renal synthesis of transforming growth factor-beta 1 and progression of renal failure. Kidney Int Suppl 1997; 63: S211-S214Adijiang A., Shimizu H., Higuchi Y. et al. Indoxyl sulfate reduces klotho expression and promotes senescence in the kidneys of hypertensive rats. J Ren Nutr 2011; 21: 105-109Adijiang A., Shimizu H., Higuchi Y. et al. Indoxyl sulfate reduces klotho expression and promotes senescence in the kidneys of hypertensive rats. J Ren Nutr 2011; 21: 105-109Namba S., Okuda Y., Morimoto A. et al. A serum indoxil sulfate is a useful predictor of chronic kidney disease. Rinsho Byori 2010; 58(5): 448-453Namba S., Okuda Y., Morimoto A. et al. A serum indoxil sulfate is a useful predictor of chronic kidney disease. Rinsho Byori 2010; 58(5): 448-453Nii-Kono T., Iwasaki Y., Uchida M. et al. Indoxil sulfate induces skeletal resistance to parathyreoid hormone in cultured osteoblastic cell. Kidney Int 2007: April,71(8); 738-743Nii-Kono T., Iwasaki Y., Uchida M. et al. Indoxil sulfate induces skeletal resistance to parathyreoid hormone in cultured osteoblastic cell. Kidney Int 2007: April,71(8); 738-743Chiang C.K., Tanaka T., Inagi R. et al. Indoxil sulfate, a representative uremic toxin suppresses erythropoietin production in a HIF-dependent manner. Lab Invest 2011; 91(11): 1564-1571Chiang C.K., Tanaka T., Inagi R. et al. Indoxil sulfate, a representative uremic toxin suppresses erythropoietin production in a HIF-dependent manner. Lab Invest 2011; 91(11): 1564-1571Shimizu H., Bolati D., Adijiang A. et al. Indoxil sulfate down-regulates renal expression of Klotho troungh production of ROS and activation of nuclear factor-kB. Am J Nephrol 2011: 33(4); 319-324Shimizu H., Bolati D., Adijiang A. et al. Indoxil sulfate down-regulates renal expression of Klotho troungh production of ROS and activation of nuclear factor-kB. Am J Nephrol 2011: 33(4); 319-324Kawakami T., Inagi R., Wada T. et al. Indoxyl sulfate inhibits proliferation of human proximal tubular cells via endoplasmic reticulum stress. Am J Physiol Renal Physiol 2010; 299(3): F568-F576Kawakami T., Inagi R., Wada T. et al. Indoxyl sulfate inhibits proliferation of human proximal tubular cells via endoplasmic reticulum stress. Am J Physiol Renal Physiol 2010; 299(3): F568-F576Shimizu H., Bolati D., Adijiang A. et al. Senescence and dysfunction of proximal tubular cells are associated with activated p 53 expression by indoxil sulfate. J Cell Physiol 2010; 299(5): 1110-1117Shimizu H., Bolati D., Adijiang A. et al. Senescence and dysfunction of proximal tubular cells are associated with activated p 53 expression by indoxil sulfate. J Cell Physiol 2010; 299(5): 1110-1117Oda T., Yung Y., Kim H. et al. PAI-1 deficiency attenuates the fibrigenic response to uretral obstruction. Kidney Int 2001; 60: 587-596Oda T., Yung Y., Kim H. et al. PAI-1 deficiency attenuates the fibrigenic response to uretral obstruction. Kidney Int 2001; 60: 587-596Wooin Lee, Richard B. Transporters and renal drug elimination. Annu Rev Pharmacol Toxicol 2004; V 44: 137-166Wooin Lee, Richard B. Transporters and renal drug elimination. Annu Rev Pharmacol Toxicol 2004; V 44: 137-166Richard B. Transporters and renal drug elimination. Annu Rev Pharmacol Toxicol 2004; V 44: 137-166Richard B. Transporters and renal drug elimination. Annu Rev Pharmacol Toxicol 2004; V 44: 137-166Taki K., Nakamura S., Miglinas M., Enomoto A., Niwa T. Accumulation of indoxyl sulfate in OAT1/3-positive tubular cells in kidneys of patients with chronic renal failure. J Ren Nutr 2006 Jul; 16(3): 199-203Taki K., Nakamura S., Miglinas M., Enomoto A., Niwa T. Accumulation of indoxyl sulfate in OAT1/3-positive tubular cells in kidneys of patients with chronic renal failure. J Ren Nutr 2006 Jul; 16(3): 199-203Hosoya K., Tachikawa M. Role organic anion/cation transporters at the blood-brain and blood-cerebrospinal fluid barriers involving uremic toxins. Clin Exper Nephrol 2011; 15(4): 478-485Hosoya K., Tachikawa M. Role organic anion/cation transporters at the blood-brain and blood-cerebrospinal fluid barriers involving uremic toxins. Clin Exper Nephrol 2011; 15(4): 478-485Бердникова Н.Г. Особенности фармакокинетики лекарственных средств при заболеваниях почек и у больных на гемодиализе. В: Кукес В.Г., ред. Клиническая фармакокинетика: теоретические, прикладные и аналитические аспекты. ГЭОТАР-Медиа, М., 2009; 186-197Бердникова Н.Г. Особенности фармакокинетики лекарственных средств при заболеваниях почек и у больных на гемодиализе. В: Кукес В.Г., ред. Клиническая фармакокинетика: теоретические, прикладные и аналитические аспекты. ГЭОТАР-Медиа, М., 2009; 186-197Niwa T. Uremic toxicity of indoxyl sulfate. Nagoya J Med Sci 2010; 72: 1 - 11Niwa T. Uremic toxicity of indoxyl sulfate. Nagoya J Med Sci 2010; 72: 1 - 11W u I.W., Hsu K.H., Lee C.C. et al. p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease. Nephrol Dial Transplant 2011; 26(3): 938-947W u I.W., Hsu K.H., Lee C.C. et al. p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease. Nephrol Dial Transplant 2011; 26(3): 938-947Yu M., Kim Y.J., Kang D.H. Indoxyl sulfate-induced endothelial dysfunction in patients with chronic kidney disease via an induction of oxidative stress. Clin J Am Soc Nephrol 2011; 6 (5): 30-39Yu M., Kim Y.J., Kang D.H. Indoxyl sulfate-induced endothelial dysfunction in patients with chronic kidney disease via an induction of oxidative stress. Clin J Am Soc Nephrol 2011; 6 (5): 30-39Miyamoto Y., Watanabe H., Otagiri M., Maruyama T. New insight into the redox properties of uremic solute indoxyl sulfate as a pro- and anti-oxidant. Ther Apher Dial 2011; 15 (2): 129-131Miyamoto Y., Watanabe H., Otagiri M., Maruyama T. New insight into the redox properties of uremic solute indoxyl sulfate as a pro- and anti-oxidant. Ther Apher Dial 2011; 15 (2): 129-131Motojima M., Nishuima F., Ikoma M. et al. Role for ”uremic toxin” in progressive loss of intact nephrons in chronic renal failure. Kidney Int 1991; 40: 461-46Motojima M., Nishuima F., Ikoma M. et al. Role for ”uremic toxin” in progressive loss of intact nephrons in chronic renal failure. Kidney Int 1991; 40: 461-46Niwa T., Miyazaki T., Hashimoto N. et al. Suppressed serum and urine levels of indoxil sulfate by oral sorbent in experimental uremic rats. Am J Nephrol 1992; 12: 201-206Niwa T., Miyazaki T., Hashimoto N. et al. Suppressed serum and urine levels of indoxil sulfate by oral sorbent in experimental uremic rats. Am J Nephrol 1992; 12: 201-206Rottenbourg J. Residual renal function and recovery of renal function in patients treated by CAPD. Kidney Int 1993; 43 (Suppl. 40): S106-S110Rottenbourg J. Residual renal function and recovery of renal function in patients treated by CAPD. Kidney Int 1993; 43 (Suppl. 40): S106-S110Gelasco A.K., Raymond J.R. Indoxyl sulfate induces complex redox alterations in mesangial cells. Am J Physiol Renal Physiol 2006 Jun; 290(6): F1551-8Gelasco A.K., Raymond J.R. Indoxyl sulfate induces complex redox alterations in mesangial cells. Am J Physiol Renal Physiol 2006 Jun; 290(6): F1551-8Motojima M., Hosokawa A., Yamato H. et al. Uraemic toxins induced proximal tubular injury via organic anion transporter 1-me-diated uptake. Br J Pharmacol 2002; 135: 555-563Motojima M., Hosokawa A., Yamato H. et al. Uraemic toxins induced proximal tubular injury via organic anion transporter 1-me-diated uptake. Br J Pharmacol 2002; 135: 555-563Motojima M., Hosokawa A., Yamamoto H. et al. Uremic toxins of organic anions upregulate PAI-1 expression by induction of NF-kB and free radicalsin proximal tubular cells. Kidney Int 2003; 63 (6): 1671-1680Motojima M., Hosokawa A., Yamamoto H. et al. Uremic toxins of organic anions upregulate PAI-1 expression by induction of NF-kB and free radicalsin proximal tubular cells. Kidney Int 2003; 63 (6): 1671-1680Кузьмин О.Б. Механизмы развития и прогрессирования нефропатии у больных сердечной недостаточностью с хроническим кардиоренальным синдромом. Нефрология 2011; 15, 2: 20-29Кузьмин О.Б. Механизмы развития и прогрессирования нефропатии у больных сердечной недостаточностью с хроническим кардиоренальным синдромом. Нефрология 2011; 15, 2: 20-29Niwa T. Role of indoxil sulfate in the progression of chronic kidneydisease and cardiovascular disease: experimental and clinical effects of oral sorbent AST-120. Ther Apher Dial 2011; 15(2); 120-124Niwa T. Role of indoxil sulfate in the progression of chronic kidneydisease and cardiovascular disease: experimental and clinical effects of oral sorbent AST-120. Ther Apher Dial 2011; 15(2); 120-124Barreto F. et al. Serum Indoxyl Sulfate Is Associated with Vascular Disease and Mortality in Chronic Kidney Disease Patients. Clin J. Of the American Society of Nephrology 2009; 4(10): 1551-1558Barreto F. et al. Serum Indoxyl Sulfate Is Associated with Vascular Disease and Mortality in Chronic Kidney Disease Patients. Clin J. Of the American Society of Nephrology 2009; 4(10): 1551-1558Fuji H., Nakai K., Fukagawa M. Role of oxidative stress and indoxil sulfate in progression of cardiovascular disease in chronic kidney disease. Ther Apher Dial 2011; 15(20): 125-128Fuji H., Nakai K., Fukagawa M. Role of oxidative stress and indoxil sulfate in progression of cardiovascular disease in chronic kidney disease. Ther Apher Dial 2011; 15(20): 125-128Dou L., Bertrand E., Cerini C. et al. The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney Int 2004; 65: 442-451Dou L., Bertrand E., Cerini C. et al. The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney Int 2004; 65: 442-451Dou L., Jourde-Chiche N., Faure V. et al. The uremic solute indoxil sulfate induces oxidative stress in endothelial cells. J Thromb Heamost 2007; 5(6); 1302-1308Dou L., Jourde-Chiche N., Faure V. et al. The uremic solute indoxil sulfate induces oxidative stress in endothelial cells. J Thromb Heamost 2007; 5(6); 1302-1308Miyamoto Y., Watanabe H., Otagiri M., Maruyama T. New Insinght into the redox properties of uremic solute indoxil sulfate as a pro and anti-oxidant. Ther Apher Dial 2011; 15(2); 129-131Miyamoto Y., Watanabe H., Otagiri M., Maruyama T. New Insinght into the redox properties of uremic solute indoxil sulfate as a pro and anti-oxidant. Ther Apher Dial 2011; 15(2); 129-131Lekawanvijit S., Adrahtas A., Kelly D.J., Kompa A.R. et al. Does indoxil sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and myocytes? Eur Heart J 2010; 31(14): 1771-1779Lekawanvijit S., Adrahtas A., Kelly D.J., Kompa A.R. et al. Does indoxil sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and myocytes? Eur Heart J 2010; 31(14): 1771-1779Schepers E., Meert N., Glorieux G. et al. P-cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production. Nephrol Dial Transplant 2007; 22: 592-596Schepers E., Meert N., Glorieux G. et al. P-cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production. Nephrol Dial Transplant 2007; 22: 592-596Meijers B.K., Claes K., Bammens B. et al. p-Cresol and cardiovascular risk in mild-to-moderate kidney disease. Clin J Am Soc Nephrol 2010; 5: 1182-1189Meijers B.K., Claes K., Bammens B. et al. p-Cresol and cardiovascular risk in mild-to-moderate kidney disease. Clin J Am Soc Nephrol 2010; 5: 1182-1189Taki K., Tsuruta Y., Niwa T. Indoxil Sulfate and atherosclerotic Risk Factors in Hemodialysis Patients. Nephrology 2007; 27(1): 30 - 35Taki K., Tsuruta Y., Niwa T. Indoxil Sulfate and atherosclerotic Risk Factors in Hemodialysis Patients. Nephrology 2007; 27(1): 30 - 35Owada S., Goto S., Bannai K., Hayashi H., Nishijima F., Niwa T. Indoxyl sulfate reduces superoxide scavenging activity in the kidneys of normal and uremic rats. Am J Nephrol 2008; 28(3): 446-54Owada S., Goto S., Bannai K., Hayashi H., Nishijima F., Niwa T. Indoxyl sulfate reduces superoxide scavenging activity in the kidneys of normal and uremic rats. Am J Nephrol 2008; 28(3): 446-54Adijiag A., Goto S., Uramoto S., Nishijima F., Niwa T. Indoxil sulfate promotes aortic calcification with expression of osteoblast-specific proteins in hypertensive rats. Nephrol Dial Transplant 2008; 23(6); 1892-1901Adijiag A., Goto S., Uramoto S., Nishijima F., Niwa T. Indoxil sulfate promotes aortic calcification with expression of osteoblast-specific proteins in hypertensive rats. Nephrol Dial Transplant 2008; 23(6); 1892-1901Yamamoto H., Tsuruoka S., Ioka T. et al. Indoxil sulfate stimulates proliferation of rat vascular smooth muscle cells. Kidney Int 2006; 69: 1780-1785Yamamoto H., Tsuruoka S., Ioka T. et al. Indoxil sulfate stimulates proliferation of rat vascular smooth muscle cells. Kidney Int 2006; 69: 1780-1785Nii-Kono T., Iwasaki Y., Uchida M., Fujieda A., Hosokawa A., Motojima M.,Yamato H., Kurokawa K., Fukagawa M. Indoxyl sulfate induces skeletal resistance to parathyroid hormone in cultured osteoblastic cells. Kidney Int 2007; 71: 738-743Nii-Kono T., Iwasaki Y., Uchida M., Fujieda A., Hosokawa A., Motojima M.,Yamato H., Kurokawa K., Fukagawa M. Indoxyl sulfate induces skeletal resistance to parathyroid hormone in cultured osteoblastic cells. Kidney Int 2007; 71: 738-743Iwasaki Y., Yamato H., Nii-Kono T., Fujieda A., Uchida M., Hosokawa A., Motojima M., Fukagawa M. Administration of oral charcoal adsorbent (AST-120) suppresses low-turnover bone progression in uraemic rats. Nephrol Dial Transplant 2006; 21: 2768-2774Iwasaki Y., Yamato H., Nii-Kono T., Fujieda A., Uchida M., Hosokawa A., Motojima M., Fukagawa M. Administration of oral charcoal adsorbent (AST-120) suppresses low-turnover bone progression in uraemic rats. Nephrol Dial Transplant 2006; 21: 2768-2774

The authors declare that there are no conflicts of interest present.